Caelin C Potts1, Adam C Retchless1, Lucy A McNamara1, Daya Marasini2, Natashia Reese3, Stephanie Swint3, Fang Hu4, Shalabh Sharma4, Amy E Blain1, David Lonsway3, Maria Karlsson3, Susan Hariri1, LeAnne M Fox1, Xin Wang1. 1. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Weems Design Studio, Inc, Contractor to Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 4. IHRC, Inc, Contractor to Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Penicillin and ciprofloxacin are important for invasive meningococcal disease (IMD) management and prevention. IMD cases caused by penicillin- and ciprofloxacin-resistant Neisseria meningitidis containing a ROB-1 β-lactamase gene (blaROB-1) and a mutated DNA gyrase gene (gyrA) have been recently reported in the United States. METHODS: We examined 2097 meningococcal genomes collected through US population-based surveillance from January 2011 to February 2020 to identify IMD cases caused by strains with blaROB-1- or gyrA-mediated resistance. Antimicrobial resistance was confirmed phenotypically. The US isolate genomes were compared to non-US isolate genomes containing blaROB-1. Interspecies transfer of ciprofloxacin resistance was assessed by comparing gyrA among Neisseria species. RESULTS: Eleven penicillin- and ciprofloxacin-resistant isolates were identified after December 2018; all were serogroup Y, sequence type 3587, clonal complex (CC) 23, and contained blaROB-1 and a T91I-containing gyrA allele. An additional 22 penicillin-resistant, blaROB-1- containing US isolates with wild-type gyrA were identified from 2013 to 2020. All 33 blaROB-1-containing isolates formed a single clade, along with 12 blaROB-1-containing isolates from 6 other countries. Two-thirds of blaROB-1-containing US isolates were from Hispanic individuals. Twelve additional ciprofloxacin-resistant isolates with gyrA T91 mutations were identified. Ciprofloxacin-resistant isolates belonged to 6 CCs and contained 10 unique gyrA alleles; 7 were similar or identical to alleles from Neisseria lactamica or Neisseria gonorrhoeae. CONCLUSIONS: Recent IMD cases caused by a dual resistant serogroup Y suggest changing antimicrobial resistance patterns in the United States. The emerging dual resistance is due to acquisition of ciprofloxacin resistance by β-lactamase-containing N. meningitidis. Routine antimicrobial resistance surveillance will effectively monitor resistance changes and spread. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: Penicillin and ciprofloxacin are important for invasive meningococcal disease (IMD) management and prevention. IMD cases caused by penicillin- and ciprofloxacin-resistant Neisseria meningitidis containing a ROB-1 β-lactamase gene (blaROB-1) and a mutated DNA gyrase gene (gyrA) have been recently reported in the United States. METHODS: We examined 2097 meningococcal genomes collected through US population-based surveillance from January 2011 to February 2020 to identify IMD cases caused by strains with blaROB-1- or gyrA-mediated resistance. Antimicrobial resistance was confirmed phenotypically. The US isolate genomes were compared to non-US isolate genomes containing blaROB-1. Interspecies transfer of ciprofloxacin resistance was assessed by comparing gyrA among Neisseria species. RESULTS: Eleven penicillin- and ciprofloxacin-resistant isolates were identified after December 2018; all were serogroup Y, sequence type 3587, clonal complex (CC) 23, and contained blaROB-1 and a T91I-containing gyrA allele. An additional 22 penicillin-resistant, blaROB-1- containing US isolates with wild-type gyrA were identified from 2013 to 2020. All 33 blaROB-1-containing isolates formed a single clade, along with 12 blaROB-1-containing isolates from 6 other countries. Two-thirds of blaROB-1-containing US isolates were from Hispanic individuals. Twelve additional ciprofloxacin-resistant isolates with gyrA T91 mutations were identified. Ciprofloxacin-resistant isolates belonged to 6 CCs and contained 10 unique gyrA alleles; 7 were similar or identical to alleles from Neisseria lactamica or Neisseria gonorrhoeae. CONCLUSIONS: Recent IMD cases caused by a dual resistant serogroup Y suggest changing antimicrobial resistance patterns in the United States. The emerging dual resistance is due to acquisition of ciprofloxacin resistance by β-lactamase-containing N. meningitidis. Routine antimicrobial resistance surveillance will effectively monitor resistance changes and spread. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Authors: José Eduardo Oliva Marín; Esmeralda Villatoro; María Jose Luna; Ana María Barrientos; Elmer Mendoza; Ana Paula S Lemos; Carlos H Camargo; Claudio T Sacchi; Marcos Paulo V Cunha; Marcelo Galas; Jean-Marc Gabastou Journal: J Antimicrob Chemother Date: 2021-04-13 Impact factor: 5.790
Authors: Peter J A Cock; Tiago Antao; Jeffrey T Chang; Brad A Chapman; Cymon J Cox; Andrew Dalke; Iddo Friedberg; Thomas Hamelryck; Frank Kauff; Bartek Wilczynski; Michiel J L de Hoon Journal: Bioinformatics Date: 2009-03-20 Impact factor: 6.937
Authors: Eva Hong; Sara Thulin Hedberg; Raquel Abad; Cecilia Fazio; Rocío Enríquez; Ala-Eddine Deghmane; Keith A Jolley; Paola Stefanelli; Magnus Unemo; Julio A Vazquez; Frédéric J Veyrier; Muhamed-Kheir Taha Journal: Antimicrob Agents Chemother Date: 2013-01-28 Impact factor: 5.191
Authors: Maria Cecília Gorla; Ana Paula Cassiolato; Juliana Maira Watanabe Pinhata; Camile de Moraes; Alejandra Corso; Paula Gagetti; Ana Paula Lemos Journal: J Med Microbiol Date: 2018-01-18 Impact factor: 2.472
Authors: Lucy A McNamara; Caelin Potts; Amy E Blain; Adam C Retchless; Natashia Reese; Stephanie Swint; David Lonsway; Maria Karlsson; Kristy Lunquest; John J Sweitzer; Xin Wang; Susan Hariri; LeAnne M Fox Journal: MMWR Morb Mortal Wkly Rep Date: 2020-06-19 Impact factor: 17.586
Authors: Jay Lucidarme; Bingqing Zhu; Li Xu; Xilian Bai; Yuan Gao; Juan José González-López; Robert Mulhall; Kevin J Scott; Andrew Smith; Paola Stefanelli; Bianca Stenmark; Paul Torpiano; Georgina Tzanakaki; Ray Borrow; Zhujun Shao Journal: PLoS One Date: 2020-12-10 Impact factor: 3.240
Authors: Avril Brooks; Jay Lucidarme; Helen Campbell; Laura Campbell; Helen Fifer; Steve Gray; Gwenda Hughes; Aiswarya Lekshmi; Gabriel Schembri; Michael Rayment; Shamez N Ladhani; Mary E Ramsay; Ray Borrow Journal: Euro Surveill Date: 2020-04
Authors: Mark R Alderson; Peter D Arkwright; Xilian Bai; Steve Black; Ray Borrow; Dominique A Caugant; Ener Cagri Dinleyici; Lee H Harrison; Jay Lucidarme; Lucy A McNamara; Susan Meiring; Marco A P Sáfadi; Zhujun Shao; David S Stephens; Muhamed-Kheir Taha; Julio Vazquez; Bingqing Zhu; Gmi Collaborators Journal: J Infect Date: 2021-11-24 Impact factor: 6.072